| Revista: | Ecletica quimica |
| Base de datos: | |
| Número de sistema: | 000552526 |
| ISSN: | 0100-4670 |
| Autores: | Ribeiro, Gislane dos Santos1 Carneiro, Amanda de Assis1 Martins, Diegue Henrique Nascimento1 Simeoni, Luiz Alberto1 Silveira, Dâmaris1 Magalhães, Pérola Oliveira1 Fonseca-Bazzo, Yris Maria1 |
| Instituciones: | 1Laboratory of Natural Products (LaProNat), Health Sciences School, Department of Pharmaceutical Sciences, University of Brasília, Brasília, DF, Brazil, |
| Año: | 2020 |
| Volumen: | 45 |
| Número: | 1 |
| Paginación: | 47-55 |
| País: | Brasil |
| Idioma: | Inglés |
| Resumen en inglés | The species Harpagophytum procumbens DC. is popularly known as devil"s claw and is widely used because of its anti-inflammatory properties that are attributed to an iridoid glycoside, the harpagoside. This medicinal plant is part of the Brazilian List of Essential Medicines, that is, it was selected and standardized for the resolution of diseases in the Brazilian public health system, SUS, and can be found in several brands. Due to the importance of quality monitoring, the objective of this study was to create and validate a method for identification and quantification of harpagoside in tablets of the devil"s claw, as well as to evaluate the content of this iridoid glycoside in three commercially available brands in Brasília, DF, Brazil. The evaluated parameters in the validation by high performance liquid chromatography (HPLC) were linearity, limits of detection and quantification, precision, selectivity, accuracy and robustness, as required by the Brazilian regulation. The developed and validated method proved satisfactory for the quality control of commercial products that present in this composition the medicinal plant. All the devil"s claw brands presented divergences regarding the quality that can interfere with therapeutics and with safety and efficacy. |
| Texto completo: | Texto completo (Ver PDF) |
